Citations

Showing 10 of 108083 citations.

Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation
Butel-Simoes, Lloyd , Haw, Tatt Jhong , Williams, Trent , Sritharan, S. , Gadre, P. , Herrmann, Joerg , Ngo, D. , Sverdlov, Aaron L. , Sritharan, Shanathan , Sverdlov, Aaron L , Herrmann, Sandra M.

Mayo Clinic

Hypertension | February 9, 2023 | Volume: 80 | Issue: 4 | Pages: 685-710

10.1161/hypertensionaha.122.17947 | PMID 36756872 Get It

Cardiovascular disease and cancer are 2 of the leading causes of death worldwide. Although improvements in outcomes have been noted for both disease entities, the success of cancer therapies has come at the cost of at times very impactful adverse events such as cardiovascular events. Hypertension has been noted as both, a side effect as well as a risk factor for the cardiotoxicity of cancer therapies. Some of these dynamics are in keeping with the role of hypertension as a cardiovascular risk factor not only for heart failure, but also for the development of coronary and cerebrovascular disease, and kidney disease and its association with a higher morbidity and mortality overall. Other aspects such as the molecular mechanisms underlying the amplification of acute and long-term cardiotoxicity risk of anthracyclines and increase in blood pressure with various cancer therapeutics remain to be elucidated. In this review, we cover the latest clinical data regarding the risk of hypertension across a spectrum of novel anticancer therapies as well as the underlying known or postulated pathophysiological mechanisms. Furthermore, we review the acute and long-term implications for the amplification of the development of cardiotoxicity with drugs not commonly associated with hypertension such as anthracyclines. An outline of management strategies, including pharmacological and lifestyle interventions as well as models of care aimed to facilitate early detection and more timely management of hypertension in patients with cancer and survivors concludes this review, which overall aims to improve both cardiovascular and cancer-specific outcomes.
Predictors of Poor Response to Radioactive Iodine Treatment in Graves’ Disease
Kawkgi, Omar El

Mayo Clinic

Clinical Thyroidology | February 9, 2023 | Volume: 35 | Issue: 02 | Pages: 57-60

10.1089/ct.2023;35.57-60 Get It

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma
Le, Hoa , Braun, Kim Van Naarden , Nowakowski, Grzegorz S. , Sermer, David , Radford, John , Townsend, William , Ghesquières, Hervé , Menne, Tobias , Porpaczy, Edit , Schusterbauer, Claudia, Yue, Lihua, Benedetti, Marc De , Hasskarl, Jens, Radford, John , Townsend, William , Fox, Christopher P. , Liu, Fei‐Fei

Mayo Clinic

Leukemia & Lymphoma | February 9, 2023 | Volume: 64 | Issue: 3 | Pages: 573-585

10.1080/10428194.2022.2160200 | PMID 36755418 Get It

Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine
Nikolova, Simona , Chong, Catherine D. , Dumkrieger, Gina , Li, Jing , Chong, Catherine D , Dumkrieger, Gina , Wu, Teresa , Schwedt, Todd J.

Mayo Clinic

Cephalalgia | February 9, 2023 | Volume: 43 | Issue: 2 | Pages: No page available

10.1177/03331024221144783 | PMID 36756979 Get It

Objectives The objective of this longitudinal study was to determine whether brain iron accumulation, measured using magnetic resonance imaging magnetic transverse relaxation rates (T2*), is associated with response to erenumab for the treatment of migraine. Methods Participants (n = 28) with migraine, diagnosed using international classification of headache disorders 3rd edition criteria, were eligible if they had six to 25 migraine days during a four-week headache diary run-in phase. Participants received two treatments with 140 mg erenumab, one immediately following the pre-treatment run-in phase and a second treatment four weeks later. T2* data were collected immediately following the pre-treatment phase, and at two weeks and eight weeks following the first erenumab treatment. Patients were classified as erenumab responders if their migraine-day frequency at five-to-eight weeks post-initial treatment was reduced by at least 50% compared to the pre-treatment run-in phase. A longitudinal Sandwich estimator approach was used to compare longitudinal group differences (responders vs non-responders) in T2* values, associated with iron accumulation. Group visit effects were calculated with a significance threshold of p = 0.005 and cluster forming threshold of 250 voxels. T2* values of 19 healthy controls were used for a reference. The average of each significant region was compared between groups and visits with Bonferroni corrections for multiple comparisons with significance defined as p < 0.05. Results Pre- and post-treatment longitudinal imaging data were available from 28 participants with migraine for a total of 79 quantitative T2* images. Average subject age was 42 ± 13 years (25 female, three male). Of the 28 subjects studied, 53.6% were erenumab responders. Comparing longitudinal T2* between erenumab responders vs non-responders yielded two comparisons which survived the significance threshold of p < 0.05 after correction for multiple comparisons: the difference at eight weeks between the erenumab-responders and non-responders in the periaqueductal gray (mean ± standard error; responders 43 ± 1 ms vs non-responders 32.5 ± 1 ms, p = 0.002) and the anterior cingulate cortex (mean ± standard error; responders 50 ± 1 ms vs non-responders 40 ± 1 ms, p = 0.01). Conclusions Erenumab response is associated with higher T2* in the periaqueductal gray and anterior cingulate cortex, regions that participate in pain processing and modulation. T2* differences between erenumab responders vs non-responders, a measure of brain iron accumulation, are seen at eight weeks post-treatment. Less iron accumulation in the periaqueductal gray and anterior cingulate cortex might play a role in the therapeutic mechanisms of migraine reduction associated with erenumab.
Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel
Taylor, Angela , Goldman, Jennifer G. , Poston, Kathleen L. , Goldman, Jennifer G , Sabbagh, Marwan Noel , Galasko, Douglas , Galvin, James E. , Leverenz, James B. , Boeve, Bradley F. , Irwin, David J. , Quinn, Joseph F.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | February 9, 2023 | Volume: 9 | Issue: 1 | Pages: No page available

10.1002/trc2.12375 | PMID 36873923 Get It

Abstract The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical Dementia Rating scale and Alzheimer's Disease Assessment Scale–Cognitive Subscale being among the most often used instruments in AD clinical trials. In contrast, there are no validated instruments for use in clinical trials of drugs for the treatment of dementia with Lewy bodies. This poses challenges for drug development because the regulatory pathway to drug approval requires demonstrable efficacy measures. In December 2021, the Lewy Body Dementia Association advisory group met with representatives from the US Food and Drug Administration to discuss the lack of approved drugs and treatments, discernment of efficacy measures, and identification of biomarkers. Highlights The Lewy Body with Dementia Association convened a listening session with the US Food and Drug Administration on dementia with Lewy bodies (DLB) and clinical trial design. Gaps include DLB‐specific measures, alpha synuclein biomarkers, and coexisting pathologies. DLB clinical trial design should focus on clinical value and disease specificity.
Wnt Signaling in the Gastrointestinal Tract in Health and Disease
Taheri, Negar , Choi, Egan L. , Nguyen, Vy Truong Thuy, Hayashi, Yujiro , Chandra, Abhishek

Mayo Clinic

Physiologia | February 9, 2023 | Volume: 3 | Issue: 1 | Pages: 86-97

10.3390/physiologia3010007 Get It

Wnt signaling involves multiple pathways that contribute to organ development, cell fate, inflammation, and normal stem cell renewal and maintenance. Although the homeostasis of stem cells in the gastrointestinal (GI) tract highly depends on the Wnt signaling pathway, this regulation is impaired in cancers and in aging. Overactive (uncontrolled) Wnt signaling can induce GI epithelial cancers such as colon and gastric cancer. Overactive Wnt signaling can also contribute to the initiation and progression of gastrointestinal stromal tumor, which is the most common human sarcoma occurring in the walls of the digestive organs, mainly the stomach and small intestine. Wnt expression is positively associated not only with the progression of oncogenesis but also with resistance to chemotherapy and radiotherapy. Of note, recent reports show that decreased Wnt signaling is related to intestinal stem cell aging and that overactivated Wnt signaling leads to gastric pacemaker stem cell aging in tunica muscularis. These findings indicate that Wnt signaling has different crucial aspects of cell fate determination with age in GI tunica mucosa and muscularis. In this review, we summarize the most recent advances in our understanding of Wnt signaling pathways and their role in regulating key aspects during development, carcinogenesis, inflammation, and aging, with the ultimate goal of identifying novel therapies.
The effect of emotion regulation on executive function
Koay, Jun Min , Meter, Anna Van

Mayo Clinic

Journal of Cognitive Psychology | February 9, 2023 | Volume: 35 | Issue: 3 | Pages: 315-329

10.1080/20445911.2023.2172417 | PMID 37791006 Get It

Structure, Substrate Specificity and Role of Lon Protease in Bacterial Pathogenesis and Survival
Kirthika, Perumalraja , Lloren, Khristine Kaith S. , Jawalagatti, Vijayakumar , Lloren, Khristine Kaith Sison , Kirthika, Perumalraja , Jawalagatti, Vijayakumar , Lee, John Hwa

Mayo Clinic

International Journal of Molecular Sciences | February 9, 2023 | Volume: 24 | Issue: 4 | Pages: 3422

10.3390/ijms24043422 | PMID 36834832 Get It

Proteases are the group of enzymes that carry out proteolysis in all forms of life and play an essential role in cell survival. By acting on specific functional proteins, proteases affect the transcriptional and post-translational pathways in a cell. Lon, FtsH, HslVU and the Clp family are among the ATP-dependent proteases responsible for intracellular proteolysis in bacteria. In bacteria, Lon protease acts as a global regulator, governs an array of important functions such as DNA replication and repair, virulence factors, stress response and biofilm formation, among others. Moreover, Lon is involved in the regulation of bacterial metabolism and toxin–antitoxin systems. Hence, understanding the contribution and mechanisms of Lon as a global regulator in bacterial pathogenesis is crucial. In this review, we discuss the structure and substrate specificity of the bacterial Lon protease, as well as its ability to regulate bacterial pathogenesis.
Rare and low-frequency coding genetic variants contribute to pediatric-onset multiple sclerosis
Horton, Mary , Shim, Joan E, Wallace, Amelia D. , Graves, Jennifer , Aaen, Gregory , Greenberg, Benjamin , Mar, Soe , Wheeler, Yolanda , Weinstock‐Guttman, Bianca , Schreiner, Teri , Tillema, Jan‐Mendelt , Casper, T. Charles , Hart, Janace, Quach, Hong , Quach, Diana , Schaefer, Catherine , Barcellos, Lisa F. , Horton, Mary K , Wallace, Amelia , Graves, Jennifer , Schreiner, Teri , Chitnis, Tanuja , Rensel, Mary R. , Weinstock‐Guttman, Bianca , Greenberg, Benjamin M , Shim, Joan E. , Waldman, Amy , Rodriguez, Moses , Krupp, Lauren , Waubant, Emmanuelle L.

Mayo Clinic

Multiple Sclerosis Journal | February 9, 2023 | Volume: 29 | Issue: 4-5 | Pages: 505-511

10.1177/13524585221150736 | PMID 36755464 Get It

Background: Rare genetic variants are emerging as important contributors to the heritability of multiple sclerosis (MS). Whether rare variants also contribute to pediatric-onset multiple sclerosis (POMS) is unknown. Objective: To test whether genes harboring rare variants associated with adult-onset MS risk ( PRF1, PRKRA, NLRP8 , and HDAC7 ) and 52 major histocompatibility complex (MHC) genes are associated with POMS. Methods: We analyzed DNA samples from 330 POMS cases and 306 controls from the US Network of Pediatric MS Centers and Kaiser Permanente Northern California for which Illumina ExomeChip genotypes were available. Using the gene-based method “SKAT-O,” we tested the association between candidate genes and POMS risk. Results: After correction for multiple comparisons, one adult-onset MS gene ( PRF1, p = 2.70 × 10 −3 ) and two MHC genes ( BRD2, p = 5.89 × 10 −5 and AGER, p = 7.96 × 10 −5 ) were significantly associated with POMS. Results suggest these are independent of HLA-DRB1*1501. Conclusion: Findings support a role for rare coding variants in POMS susceptibility. In particular, rare minor alleles within PRF1 were more common among individuals with POMS compared to controls while the opposite was true for rare variants within significant MHC genes, BRD2 and AGER . These genes would not have been identified by common variant studies, emphasizing the merits of investigating rare genetic variation in complex diseases.
Female Hormone Therapy and Risk of Intracranial Hemorrhage From Cerebral Cavernous Malformations
Zuurbier, Susanna M. , Santos, Alejandro N. , Flemming, Kelly D. , Schmidt, Börge , Sure, Ulrich , Dammann, Philipp , Sure, Ulrich , Santos, Alejandro N. , Flemming, Kelly D , Jabbarli, Ramazan , Lanzino, Giuseppe

Mayo Clinic

Neurology | February 8, 2023 | Volume: 100 | Issue: 16 | Pages: No page available

10.1212/wnl.0000000000206888 | PMID 36754635 Get It